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Introduction {#sec001}
============

The mammalian mitogenome comprises a set of 13 genes coding for proteins of the electron transport chain, two genes specifying for 12S- and 16S rRNAs, 22 for tRNAs, and a non-coding D-loop region, altogether encompassing approximately 16,600 bp \[[@pone.0177403.ref001]\]. The mt-proteins of the electron transport chain together with other 80 proteins encoded by nuclear genes \[[@pone.0177403.ref002]\] comprise the oxidative phosphorylation (OXPHOS) machinery consisting of five multimeric protein complexes, one exclusively containing nuclear proteins (complex II) and four other (I, III, IV and V) with nuclear and mitochondrial proteins \[[@pone.0177403.ref003]\].

As OXPHOS dysfunction accounts for serious impairments in energy production, mt-genes have been subject to strong evolutionary constraints and a drastically restricted variability under the effect of strong negative selection \[[@pone.0177403.ref004]--[@pone.0177403.ref006]\] despite punctual cases of positive selection and molecular adaptations to extreme metabolic demands \[[@pone.0177403.ref007]--[@pone.0177403.ref011]\].

Most pathogenic mt-mutations are eliminated or maintained with significantly reduced frequencies in populations \[[@pone.0177403.ref005],[@pone.0177403.ref006],[@pone.0177403.ref012]\]. Analyses of a large set of human mitochondrial genomes showed that amino acid variants with predicted high pathogenicity were rarely detected, while those with a predicted low pathogenicity emerged several times during human evolutionary diversification \[[@pone.0177403.ref013]\]. Several mt-mutations are associated with metabolic disorders, human diseases or syndromes, like Leber Hereditary Optic Neuropathy (LHON), Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS), Exercise Intolerance (EXIT), Mitochondrial Myopathy, Dystonia, Leigh Disease (LD), Alzheimer\'s Disease, Parkinson's Disease, and Progressive Encephalomyopathy \[[@pone.0177403.ref014]--[@pone.0177403.ref018]\]. However, only a fraction of these mutations has been confirmed to be etiologically pathogenic by independent clinical studies, robust statistical analyses and well-known biochemical effects while most mutations are only reported to be associated with human pathologies without a clear causal relation with disease \[[@pone.0177403.ref017]\].

A phylogenetic approach might be useful for identifying mt-mutations etiologically responsible for OXPHOS damage because protein regions under strong functional and structural constraints are highly conserved \[[@pone.0177403.ref019]\]. In fact, some methods designed for predicting the pathogenicity and severity of mutations consider evolutionary conservation of amino acid residues, but usually include a large set of distantly related organisms \[[@pone.0177403.ref020],[@pone.0177403.ref021]\], likely with disparate physiological demands. On the other hand, we would expect that mutations similar to those associated with pathologic conditions in humans would also reduce fitness in very closely related species, being therefore subject to purifying selection \[[@pone.0177403.ref012]\]. However, this would not be necessarily true if the physiological characteristics of other species were unaffected by these mutations or other compensatory mutations nullified their pathogenic effects \[[@pone.0177403.ref022]\]. Conversely, non-deleterious mutations might have subsisted under neutral selection, with a high probability of being maintained across different taxa and, consequently to the lack of severe constraints, higher rates of amino acid substitutions would be expected. In this scenario, mapping the occurrence of disease-associated mutations in a phylogenetic tree of closely related species may shed light on the evolutionary constraints affecting these genes \[[@pone.0177403.ref002],[@pone.0177403.ref003],[@pone.0177403.ref022]\] as well as assessing their effect as causal factors.

In this paper, we analyze the diversity of the mitogenome in 139 primate species to test whether disease-associated mutations in humans were predominantly concentrated in codons under strong evolutionary constraints and to trace these changes within a phylogenetic approach, including ancestry, number of independent events and polarity with respect to their presumed or confirmed pathogenicity in humans.

Material and methods {#sec002}
====================

Primate phylogeny based on mitogenomes {#sec003}
--------------------------------------

One hundred and forty-eight reference sequences of complete mitogenomes of 139 primate species were downloaded from GenBank ([S1 Table](#pone.0177403.s005){ref-type="supplementary-material"}). Taxonomic sampling included all living primate families, all hominid living species, three fossil hominids (*Homo heidelbergensis*, *Homo neanderthalensis* and the unnamed *Homo* from Denisova) and two fossil lemurs (*Palaeopropithecus ingens* and *Megaladapis edwardsi*).

Separate alignments of the 13 protein-coding *mt*-genes were run with Muscle \[[@pone.0177403.ref023]\] and checked manually with Mega v.6.0 \[[@pone.0177403.ref024]\]. These alignments were subsequently concatenated in a single dataset with 11,406 bp for Maximum Likelihood (ML) phylogenetic reconstructions. ML was independently performed with PhyML v.3.1 in SeaView v.4.5.4 \[[@pone.0177403.ref025],[@pone.0177403.ref026]\] and the GARLI online platform \[[@pone.0177403.ref027]\], with estimations of approximate likelihood-ratio tests (aLRT) using the General Time Reversible model with gamma distribution and invariable sites (GTR+Γ+I), which was indicated as the best evolutionary model by ModelGenerator v.0.85 \[[@pone.0177403.ref028]\]. The GTR+Γ+I model assumes a symmetric substitution matrix, in which each pair of nucleotide substitutions has a different rate, nucleotides occurring at different frequencies, rates varying among sites according a gamma distribution and some sites remaining unchanged \[[@pone.0177403.ref029]\]. The alignment of the 13 concatenated genes is available in [S1 File](#pone.0177403.s003){ref-type="supplementary-material"}.

Analyses of evolutionary conservation of codons and amino acid residues {#sec004}
-----------------------------------------------------------------------

The evolutionary conservation of each aligned codon position and the amino acid residue therein encoded was estimated with three different indices, named Ind1, Ind2, Ind3. The simplest index (Ind1) recorded the number of different amino acids per aligned codon position. Ind2 estimated the total number of missense mutations per aligned codon position along primate radiation using SLAC in DataMonkey server \[[@pone.0177403.ref030],[@pone.0177403.ref031]\]. Finally, Ind3 reported the standardized evolutionary rates per aligned residue position with ConSurf server \[[@pone.0177403.ref032],[@pone.0177403.ref033]\] using a Rate4Site algorithm under an empirical Bayesian methodology \[[@pone.0177403.ref034],[@pone.0177403.ref035]\]. The Rate4Site algorithm uses the tree topology and branch lengths to calculate rates of amino acid substitutions per site. The resulting conservation scores are usually highly correlated with dN/dS (ratio of non-synonymous substitutions per non-synonymous sites to synonymous substitutions per synonymous sites) scores based on the coding DNA sequences \[[@pone.0177403.ref035]\].

Additionally, TreeSAAP was used for investigating whether, along primate diversification, non-synonymous substitutions in codon positions with confirmed and reported disease-associated mutations resulted in substitutions of amino acids with radically different physicochemical properties \[[@pone.0177403.ref036],[@pone.0177403.ref037]\]. Analysis was carried out testing 31 physicochemical amino acid properties, and only changes of categories 6, 7 and 8 with z-scores \> 3.09 (p \< 0.001) were considered to be radical changes \[[@pone.0177403.ref036],[@pone.0177403.ref037]\]. With TreeSAAP we estimated, for each residue position, the number of independent amino-acid substitutions resulting in changes of radical physicochemical properties, and the maximum number of physicochemical properties radically affected in each residue position. Amino acid substitutions resulting in radically different physicochemical properties would be expected to occur very rarely in residue positions under strong functional constraints while substitutions by amino acids with similar properties would be expected to be frequent.

SLAC was used for identifying codons under negative selection. SLAC reconstructs codon ancestral sequences, estimates the normalized expected and observed numbers of synonymous and non-synonymous substitutions and computes dN/dS ratios. A p-value derived from a two-tailed extended binomial distribution is used to assess significance of dN and dS differences (α = 0.05). Codons are considered to be negatively selected when dN \< dS.

Disease-associated mutations per aligned codon position {#sec005}
-------------------------------------------------------

The disease-associated missense mutations found in 13 protein-coding, human mt-genes were downloaded from UniProt and MITOMAP databases in November 2016 \[[@pone.0177403.ref017],[@pone.0177403.ref038],[@pone.0177403.ref039]\] for analyzing Ind1, Ind2 and Ind3 data. Two kinds of disease-associated mutations were considered according to MITOMAP criteria: (i) "reported" (when one or more publications considered a mutation as possibly pathogenic) and (ii) "confirmed" (when two or more independent laboratories reported the pathogenicity of a specific mutation, and the mitochondrial research community generally accepted it as being pathogenic). This classification will be used throughout this report.

The frequency distribution of each index (Ind1, Ind2 and Ind3) for (i) all aligned codon positions, (ii) aligned codon positions with reported disease-associated mutations, and (iii) aligned codon positions with confirmed disease-associated mutations was plotted to test whether disease-associated mutations were predominantly concentrated in highly conserved positions. The Kolmogorov-Smirnov tests were used for comparing the distributions of i-, ii- and iii- groups of aligned codon positions per index.

A t-test was used for investigating whether predicted pathogenicity scores of confirmed disease-associated mutations, estimated with MutPred \[[@pone.0177403.ref021]\] in a previous study \[[@pone.0177403.ref013]\], were higher than for reported disease-associated mutations.

Results {#sec006}
=======

Phylogenetic reconstruction {#sec007}
---------------------------

ML analyses showed a very similar phylogenetic topology to previous reports \[[@pone.0177403.ref007],[@pone.0177403.ref040]--[@pone.0177403.ref042]\] with high node support. A detailed description of this topology is available in [S1 Fig](#pone.0177403.s001){ref-type="supplementary-material"}. A newick formatted tree is available in [S2 File](#pone.0177403.s004){ref-type="supplementary-material"}.

Variation and evolution of primate mt-genes {#sec008}
-------------------------------------------

The mt-*CO1* gene was the most evolutionarily conserved of all 13 mt-genes (mean GTR+Γ+I distance = 0.253) while mt*-ATP8* was the most variable (mean GTR+Γ+I distance = 0.582). A significant, negative correlation was observed between gene size and mean GTR+Γ+I distance ([Fig 1A](#pone.0177403.g001){ref-type="fig"}; r^2^ = 0.461; p = 0.011) but not between gene size and proportion of codons under negative selection ([Fig 1B](#pone.0177403.g001){ref-type="fig"}; r^2^ = 0.136; p = 0.214).

![Gene size, genetic distance and codons under negative selection.\
(A) Significant, positive correlation between mitochondrial gene size and mean GTR+Γ+I distance (r^2^ = 0. 461; p = 0.011). (B) Non-significant, negative correlation between gene size and percentage of codons under negative selection (r^2^ = 0.136; p = 0.214).](pone.0177403.g001){#pone.0177403.g001}

Except for mt-*ATP6*, mt-*CO1*, mt-*CO2*, mt-*CO3* and mt-*ND4L*, where indels were absent, 45 indels occurring as independent evolutionary events were clustered in highly variable gene regions ([S2 Table](#pone.0177403.s006){ref-type="supplementary-material"}). This was the case of codon 85 of mt-*ND3* with one deletion in bushbabies (*Galago*) and three independent insertions between codon 85 and 86 in mouse lemurs (*Microcebus*) and baboons (*Papio*). The mt-*ND4* gene showed four independent deletions of codon 47 in the New World monkeys (Platyrrhini), bushbabies (*Galago*), lorises (*Loris*) and gibbons (*Nomascus*), as well as two independent deletions of the adjacent codons 49 and 50 in aye-aye (*Daubentonia madagascariensis*) and lineage including galagos and lorises (Lorisiformes). Twelve independent deletions and eight independent insertions occurred between codons 105 and 115 of the mt-*ND6* gene in 20 taxa.

Analyses of 3,786 aligned codon positions showed that the number of different amino acids coded per position (Ind1) varied from 1 to 14 (mode = 1; mean = 3.020; S.D. = 2.408; [Fig 1](#pone.0177403.g001){ref-type="fig"}) while the number of non-synonymous substitutions per aligned codon position (Ind2) varied from 0 to 76 (mode = 0; mean = 6.564; S.D. = 9,318). The evolutionary rate of each amino acid position (Ind3) varied from − 0.719 to 6.529 (mode = − 0.707; median = − 0.479; mean of standardized rates = 0; S.D. = 1). The distributions of Ind1, Ind2 and the transformed Ind3 (for including only positive estimates) fitted well to the exponential distributions for Ind1 (χ^2^ = 272.931, df = 14, p \< 0.001), Ind2 (χ^2^ = 711.737; df = 7; p \< 0.001) and Ind3 (χ^2^ = 591.790; df = 8; p \< 0.001). In 1,443 (38.1%) of aligned codon positions, missense substitutions were not observed across primate diversification because only a single amino acid was coded in all species. On the other hand, 3,381 (88.9%) aligned codon positions appeared to be under negative selection with SLAC.

Aligned codon positions and disease-associated mutations in humans {#sec009}
------------------------------------------------------------------

Missense substitutions associated with human diseases were identified in 220 aligned codon positions ([S3 Table](#pone.0177403.s007){ref-type="supplementary-material"}). Twenty-eight aligned codon positions showed mutations classified as "confirmed" and 192 as "reported" by MITOMAP and UNIPROT. The predicted pathogenicity scores of the confirmed disease-associated mutations were significantly higher than those of reported disease-associated mutations (t = 2.956; d.f. = 226; p = 0.003; [Fig 2](#pone.0177403.g002){ref-type="fig"}). Kolmogorov-Smirnov tests of Ind1, Ind2 and Ind3 consistently showed that aligned codon positions with confirmed disease-associated mutations were not randomly distributed but concentrated among the most evolutionary conserved positions. On the other hand, Ind1, Ind2 and Ind3 estimates showed that the aligned codon positions with reported disease-associated mutations were not significantly concentrated and were not significantly different from the whole set of aligned codon positions ([Fig 3](#pone.0177403.g003){ref-type="fig"}; [Table 1](#pone.0177403.t001){ref-type="table"}). All aligned codon positions with confirmed disease-associated mutations were found to be under negative selection with SLAC, contrary to only 85.5% of aligned codon positions with reported disease-associated mutations, similarly to found for all positions of all mt-genes (88.9%).

![Predicted pathogenicity scores.\
Significant difference between means of predicted pathogenicity scores between confirmed disease-associated mutations and reported disease-associated mutations (t = 2.956; d.f. = 226; p = 0.003).](pone.0177403.g002){#pone.0177403.g002}

![Indices of evolutionary conservation.\
Frequency distributions of Ind 1 (left), Ind2 (middle) Ind3 (right) of three groups of aligned codon positions (all positions, positions with confirmed disease-associated mutations and positions with reported disease-associated mutations).](pone.0177403.g003){#pone.0177403.g003}

10.1371/journal.pone.0177403.t001

###### Comparisons of Ind1, Ind2 and Ind2 distributions.

![](pone.0177403.t001){#pone.0177403.t001g}

                   Ind1    Ind2      Ind3                                                      
  ---------------- ------- --------- ---------- -------- --------- --------- ------- --------- ---------
  **All codons**   \-      4.3E-04   0.888      \-       2.6E-04   0.1724    \-      4.1E-05   0.666
  **Confirmed**    0.397   \-        4.6 E-04   0.409    \-        4.6E-04   0.457   \-        1.0E-04
  **Reported**     0.043   0.420     \-         0.0817   0.420     \-        0.054   0.465     \-

Kolmogorov-Smirnov test for comparing distributions of estimates Ind1, Ind2 and Ind2 between sets of all aligned codon positions (All codons), aligned codon positions with confirmed disease-associated mutations (Confirmed), and aligned codon positions with reported disease-associated mutations (Reported). The *D* statistics of each test are shown above diagonals and respective *p*-values are shown below diagonals.

Aligned codon positions with confirmed disease-associated mutations in humans {#sec010}
-----------------------------------------------------------------------------

Of the 28 aligned codon positions with confirmed disease-associated mutations, 78.6% (n = 22) were invariant in all reference sequences of the primate species herein analyzed. Of the six positions with missense mutations, two were found to be highly variable across primate taxa. This was the case of codon positions 34 and 45 of mt-*ND3* with missense substitutions m.10158T\>C (S34P) and m.10191T\>C (S45P) accounting for confirmed disease-associated mutations with Leigh Disease in humans. In these two positions, serine is the only coded residue in normal humans. These positions, however, were found to be highly variable along primate evolution (Ind3~34~ = 1.442; Ind3~45~ = 0.882), with 20 and 15 non-synonymous substitutions, coding for eight and six amino acids, respectively, albeit none encoding proline. Among the 20 non-synonymous substitutions affecting codon 34 of mt-*ND3*, 10 resulted in radical changes in amino acid physicochemical properties (affecting up to seven different properties), and among the 15 non-synonymous substitutions affecting codon 45 of mt-*ND3*, six resulted in radical changes in amino acid physicochemical properties (affecting up to 12 different properties).

Confirmed disease-associated mutations in humans were found to occupy two slightly variable aligned codon positions, but with amino acid physicochemical properties highly conserved along primate evolution. This was the case of the m.8528T\>C substitution in the partially overlapping codons 1 of mt-*ATP6* and 54 of mt-*ATP8* resulting in M1T and W54R, respectively, and associated with neuromuscular disorder and infantile cardiomyopathy ([Fig 4](#pone.0177403.g004){ref-type="fig"}). Along the primate diversification, the amino acid substitutions in these residue positions did not result in any radical change in physicochemical properties. A phylogenetic reconstruction indicated that ATG was the ancestral codon 1 of mt-*ATP6* and TGA the ancestral codon of codon 54 of mt-*ATP8*. Two independent m.8527A\>G substitutions resulted in identical amino acid replacements (M1V) in the first residue of the ATP synthase F~0~-a polypeptide in the Wallace\'s tarsier (*Tarsius wallacei*) and Hubbard\'s sportive lemur (*Lepilemur hubbardorum*), while m.8527A\>G in codon 53 of mt-*ATP8* was a samesense mutation.

![Overlapping mutations in mt-*ATP6* and mt-*ATP8*.\
Comparison between a confirmed disease-associated missense mutation in humans (m.8528T\>C; left) and a mutation in an adjacent region (m.8527A\>G, right) in two non-human primates, *Tarsius wallacei* and *Lepilemur hubbardorum*. These mutations affected nucleotide positions in overlapping coding regions of mt-*ATP6* (in blue, above) and mt-*ATP8* (in red, below). m.8528T\>C is a missense mutation in both genes, while m.8527A\>G is a missense mutation only in mt-*ATP6*.](pone.0177403.g004){#pone.0177403.g004}

Moreover, in the aligned codon position 64 of mt-*ND6*, three different missense mutations (m.14482C\>A; M64I, m.14482C\>G; M64I, and m.14484T\>C; M64V) resulting in substitutions of isoleucine and valine for methionine, have been confirmed to be associated with LHON in humans. A phylogenetic reconstruction indicated that codon 64 has been variable along primate evolution, with TTG being the most ancestral triplet, coding for leucine, and with all five other leucine codons being present along different lineages. Methionine is therefore a derived trait (L64M) resulting from two different, independent missense mutations, one in the fat-tailed dwarf lemur (*Cheirogaleus medius*) lineage (CTG→ATG) and another in the ancestor of all anthropoid (simiiforme) primates (TTG→ATG). Within this latter lineage, methionine has been coded by both ATG and ATA. The two non-synonymous mutations affecting codon 64 of mt-*ND6* did not result in any radical change in physicochemical properties.

In none of the four above mentioned codon positions, specific amino acids from confirmed disease-associated mutations were found in the non-human primate species herein studied. This, however, was not the case of both mt-*ND1* missense mutations m.3635G\>A (S110N) and m.3700G\>A (A132T), identified as confirmed disease-associated mutations with LHON in humans. Asparagine and threonine, resulting from these mutations were deduced from the reference sequence of the sooty mangabey (*Cercocebus atys*) and the Bornean orangutan (*Pongo pygmaeus*), respectively, apparently without evidence of a pathologic condition in these species. Furthermore, in another available mt-*ND1* sequence of *C*. *atys* (KP090062) asparagine was also found at position 110, showing that this substitution was not a peculiarity of the reference specimen. Similarly, in all four other available mt-*ND1* sequences of *P*. *pygmaeus* (NC_001646, X97713.1, X97713.1 and X97713.1) threonine was coded by codon 132, while in four other sequences of the Sumatran orangutan (*Pongo abelli*; X97713.1, X97713.1, X97713.1 and X97713.1) this position coded for alanine ([Fig 5A](#pone.0177403.g005){ref-type="fig"}). The substitution of serine by asparagine, the only amino acid change in residue position 110 of NADH1, did not result in radical changes in physicochemical properties. Conversely, two of the three amino acid substitutions affecting residue 132 of NADH1 resulted in radical changes in physicochemical properties (affecting up to three different properties); the substitution of alanine by threonine, as observed in the linage leading to *P*. *pygmaeus*, corresponded to a radical change in the tendencies of forming alpha-helices.

![Phylogeny of the Hominidae, showing two disease-associated mutations in modern humans (*Homo sapiens*) with similar counterparts in other hominids.\
A. Confirmed, disease-associated A132T mutation in mt-*ND1* showing its occurrence in the Bornean orangutans (*Pongo pygmaeus*). B. Reported, disease-associated, A64S mutation in mt-*ND1*, showing that all hominids show serine in residue 64 of NADH1, except modern humans and closely related Neanderthals.](pone.0177403.g005){#pone.0177403.g005}

Aligned codon positions with reported disease-associated mutations in the human {#sec011}
-------------------------------------------------------------------------------

Among the 192 aligned codon positions with reported disease-associated mutations in the human, only 35.9% (n = 69) did not show missense mutations, similarly to the proportion of codon positions without missense substitutions of all mt-genes (38.114%). In the other 123 aligned codon positions, 88 (71.5%) mutations were found to code for amino acids associated with human disease in at least one non-human primate species ([Table 2](#pone.0177403.t002){ref-type="table"}; [S3 Table](#pone.0177403.s007){ref-type="supplementary-material"} and [S2 Fig](#pone.0177403.s002){ref-type="supplementary-material"}). This was the case of a missense mutation in mt-*CO1* codon 4 (m.5913G\>A; D4N) substituting asparagine for aspartic acid, and associated with human prostate cancer and hypertension. Asparagine was estimated to be the ancestral primate residue for this position with SLAC, and was also present in 119 other primate species herein analyzed. Similarly, a missense mutation in codon 159 of mt-*ND5* (m.12811T\>C; Y159H) substituting histidine for tyrosine was reported to be a likely LHON factor \[[@pone.0177403.ref043]\]. However, the presence of histidine in NADH5 residue position 159 independently appeared 11 times along primate diversification, in 70 different species herein analyzed.

10.1371/journal.pone.0177403.t002

###### Number of aligned codon positions occupied by disease-associated mutations.

![](pone.0177403.t002){#pone.0177403.t002g}

                                                                            Gene        Total number of aligned codon positions   Positions with invariable residues   Positions with variable residues   Positions with disease-associated residues in primates other than *H*.*sapiens*   Positions with disease-associated residues in catarrhines other than *H*.*sapiens*   Positions with disease-associated residues in hominids other than *H*.*sapiens*   Positions with disease-associated residues in extinct *Homo* species
  ------------------------------------------------------------------------- ----------- ----------------------------------------- ------------------------------------ ---------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ --------------------------------------------------------------------------------- ----------------------------------------------------------------------
  **Aligned codon positions with confirmed disease-associated mutations**   mt-*ATP6*   4                                         3                                    1                                  0                                                                                 0                                                                                    0                                                                                 0
  mt-*ATP8*                                                                 0           \-                                        \-                                   \-                                 \-                                                                                \-                                                                                   \-                                                                                
  mt-*CO1*                                                                  0           \-                                        \-                                   \-                                 \-                                                                                \-                                                                                   \-                                                                                
  mt-*CO2*                                                                  0           \-                                        \-                                   \-                                 \-                                                                                \-                                                                                   \-                                                                                
  mt-*CO3*                                                                  0           \-                                        \-                                   \-                                 \-                                                                                \-                                                                                   \-                                                                                
  mt-*CYB*                                                                  3           3                                         0                                    0                                  0                                                                                 0                                                                                    0                                                                                 
  mt-*ND1*                                                                  9           7                                         2                                    2                                  2                                                                                 1                                                                                    0                                                                                 
  mt-*ND2*                                                                  0           0                                         0                                    0                                  0                                                                                 0                                                                                    0                                                                                 
  mt-*ND3*                                                                  3           1                                         2                                    0                                  0                                                                                 0                                                                                    0                                                                                 
  mt-*ND4*                                                                  1           1                                         0                                    0                                  0                                                                                 0                                                                                    0                                                                                 
  mt-*ND4L*                                                                 1           1                                         0                                    0                                  0                                                                                 0                                                                                    0                                                                                 
  mt-*ND5*                                                                  3           3                                         0                                    0                                  0                                                                                 0                                                                                    0                                                                                 
  mt-*ND6*                                                                  4           3                                         1                                    0                                  0                                                                                 0                                                                                    0                                                                                 
  Total                                                                     28          22                                        6                                    2                                  2                                                                                 1                                                                                    0                                                                                 
  **Aligned codon positions with reported disease-associated mutations**    mt-*ATP6*   19                                        6                                    13                                 11                                                                                7                                                                                    4                                                                                 0
  mt-*ATP8*                                                                 8           1                                         7                                    6                                  5                                                                                 0                                                                                    0                                                                                 
  mt-*CO1*                                                                  26          11                                        15                                   13                                 13                                                                                3                                                                                    1                                                                                 
  mt-*CO2*                                                                  14          4                                         10                                   7                                  6                                                                                 1                                                                                    1                                                                                 
  mt-*CO3*                                                                  12          3                                         9                                    6                                  6                                                                                 2                                                                                    0                                                                                 
  mt-*CYB*                                                                  22          11                                        11                                   6                                  6                                                                                 5                                                                                    1                                                                                 
  mt-*ND1*                                                                  25          10                                        15                                   10                                 10                                                                                7                                                                                    1                                                                                 
  mt-*ND2*                                                                  12          2                                         10                                   4                                  1                                                                                 1                                                                                    1                                                                                 
  mt-*ND3*                                                                  4           1                                         3                                    2                                  2                                                                                 1                                                                                    1                                                                                 
  mt-*ND4*                                                                  9           2                                         7                                    5                                  4                                                                                 4                                                                                    1                                                                                 
  mt-*ND4L*                                                                 3           2                                         1                                    1                                  1                                                                                 0                                                                                    0                                                                                 
  mt-*ND5*                                                                  26          12                                        14                                   11                                 10                                                                                7                                                                                    1                                                                                 
  mt-*ND6*                                                                  12          5                                         7                                    6                                  5                                                                                 1                                                                                    0                                                                                 
  Total                                                                     192         70                                        122                                  88                                 76                                                                                36                                                                                   8                                                                                 

Several amino acids coded for by reported disease-associated mutations in humans were also coded for by 76 aligned codon positions in at least one Old World primate (catarrhine) species. Similarly, this was observed at 36 aligned codon positions, 24 in great ape species and eight in species of the genus *Homo* ([Table 2](#pone.0177403.t002){ref-type="table"} and [S3 Table](#pone.0177403.s007){ref-type="supplementary-material"}). The mean number of independent appearances, per codon position, of amino acids resulting from reported disease-associated mutations in the human equaled 1.7 (min = 0; max = 17; S.D. = 2.844), and the mean number of primate species with amino acid variants resulting from reported disease-associated mutations in the human equaled 11.1 per codon position (min = 0; max = 121; S.D. = 23.780; [Fig 6](#pone.0177403.g006){ref-type="fig"}).

![Recurrence of reported disease-associated mutations in the human across primate phylogeny.\
Left: Number of independent occurrences, per codon position, of amino acids accounting for reported disease-associated mutations in the human across primate phylogeny. Right: Number of species with amino acids accounting for reported disease-associated mutations in the human.](pone.0177403.g006){#pone.0177403.g006}

Sixty-nine aligned codon positions where amino acid replacements resulted in reported disease-associated mutations were found to be completely conserved (with Ind1 = 1 and Ind2 = 0) and under negative selection along primate evolution ([Table 3](#pone.0177403.t003){ref-type="table"}). Most of these mutations in these codons were associated with MELAS (n = 14), LHON (n = 13), Leigh Disease (n = 9), and EXIT (n = 5). Non-synonymous substitutions that did not result in radical changes in amino acid properties were found to occur in other 14 aligned codon positions where amino acid replacements resulted in reported disease-associated mutations in humans ([Table 4](#pone.0177403.t004){ref-type="table"}).

10.1371/journal.pone.0177403.t003

###### Reported disease-associated, missense mutations occurring in aligned codons positions with single invariant amino acid residues along primate evolution.

![](pone.0177403.t003){#pone.0177403.t003g}

  Gene        Nucleotide substitution   Codon position in humans   Amino acid substitution   Associated phenotype in humans
  ----------- ------------------------- -------------------------- ------------------------- ---------------------------------------------------------
  mt*-ATP6*   m.8561C\>G                12                         P12R                      Ataxia with neuropathy, DM, SNHL and hypogonadism
  mt*-ATP6*   m.8741T\>G                72                         L72R                      MILS
  mt*-ATP6*   m.8851T\>C                109                        W109R                     BSN
  mt*-ATP6*   m.8969G\>A                148                        S148N                     [MLASA](http://www.uniprot.org/diseases/DI-04410)
  mt*-ATP6*   m.9016A\>G                164                        I164V                     LHON
  mt*-ATP6*   m.9035T\>C                170                        L170P                     Ataxia syndromes
  mt*-ATP6*   m.9191T\>C                222                        L222P                     LD
  mt*-ATP8*   m.8528T\>C                55                         W55R                      Mitochondrial complex V deficiency
  mt*-CO1*    m.5935A\>G                11                         N11S                      PC
  mt*-CO1*    m.6277G\>A                125                        G125D                     CC
  mt*-CO1*    m.6328C\>T                142                        S142F                     EXIT
  mt*-CO1*    m.6489C\>A                196                        L196I                     Therapy-Resistant Epilepsy
  mt*-CO1*    m.6597C\>A                232                        Q232K                     MELAS-like syndrome
  mt*-CO1*    m.6955G\>A                351                        G351D                     Mild EXIT and moderate mental retardation
  mt*-CO1*    m.7023G\>A                374                        V374M                     MELAS-like syndrome
  mt*-CO1*    m.7041G\>A                380                        V380I                     PC
  mt*-CO1*    m.7305A\>C                468                        M468L                     PC
  mt*-CO2*    m.7637G\>A                18                         E18K                      PD risk factor
  mt*-CO2*    m.7671T\>A                29                         M29K                      MM
  mt*-CO2*    m.7877A\>C                98                         K98Q                      PEG
  mt*-CO2*    m.7989T\>C                135                        L135P                     Rhabdomyolysis
  mt*-CO3*    m.9267G\>C                21                         A21P                      MIDD
  mt*-CO3*    m.9544G\>A                113                        G113E                     Sporadic bilateral optic neuropathy
  mt*-CO3*    m.9789T\>C                195                        S195P                     Myopathy
  mt*-CYB*    m.14841A\>G               32                         N32S                      LHON
  mt*-CYB*    m.14846G\>A               34                         G34S                      EXIT
  mt*-CYB*    m.15024G\>A               93                         C93Y                      Possible DEAF modifier
  mt*-CYB*    m.15092G\>A               116                        G116S                     MELAS
  mt*-CYB*    m.15197T\>C               151                        S151P                     EXIT
  mt*-CYB*    m.15209T\>C               155                        Y155H                     Prader-Willi syndrome
  mt*-CYB*    m.15243G\>A               166                        G166E                     HCM
  mt*-CYB*    m.15615G\>A               290                        G290D                     EXIT, and Antimycin resistance
  mt*-CYB*    m.15635T\>C               297                        S297P                     Polyvisceral failure
  mt*-CYB*    m.15699G\>C               318                        R318P                     Muscle Weakness SNHL and Migraine
  mt*-CYB*    m.15762G\>A               339                        G339E                     MM
  mt*-ND1*    m.3380G\>A                25                         R25Q                      MELAS
  mt*-ND1*    m.3388C\>A                28                         L28M                      Maternally Inherited Nonsyndromic Deafness
  mt*-ND1*    m.3418A\>G                38                         N38D                      AMegL
  mt*-ND1*    m.3481G\>A                59                         E59K                      MELAS / Progressive Encephalomyopathy
  mt*-ND1*    m.3688G\>A                128                        A128T                     LD
  mt*-ND1*    m.3946G\>A                214                        E214K                     MELAS
  mt*-ND1*    m.3949T\>C                215                        Y215H                     MELAS
  mt*-ND1*    m.3959G\>A                218                        G218D                     MELAS
  mt*-ND1*    m.3995A\>G                230                        N230S                     MELAS
  mt*-ND1*    m.4160T\>C                286                        M286P                     LHON
  mt*-ND2*    m.4633C\>G                55                         A55G                      LHON
  mt*-ND2*    m.5244G\>A                259                        G259S                     LHON
  mt*-ND3*    m.10254G\>A               66                         D66N                      LD
  mt*-ND4*    m.11232T\>C               160                        L160P                     CPEO
  mt*-ND4*    m.11375A\>C               206                        K206Q                     sCJD
  mt*-ND4L*   m.10543A\>G               25                         H25R                      LHON
  mt*-ND4L*   m.10591T\>G               41                         F41C                      LHON
  mt*-ND5*    m.12770A\>G               145                        E145G                     MELAS
  mt*-ND5*    m.12782T\>G               149                        I149S                     LHON
  mt*-ND5*    m.12848C\>T               171                        A171V                     LHON
  mt*-ND5*    m.13042G\>A               236                        A236T                     Optic neuropathy, retinopathy, and LD
  mt*-ND5*    m.13045A\>C               237                        M237L                     MELAS, LHON, and Leigh overlap syndrome
  mt*-ND5*    m.13063G\>A               243                        V243I                     Adult-onset Encephalopathy and Ataxia
  mt*-ND5*    m.13084A\>T               250                        S250C                     MELAS, LD
  mt*-ND5*    m.13094T\>C               253                        V253A                     Ataxia with PEO, MELAS, LD, myoclonus and fatigue
  mt*-ND5*    m.13379A\>C               348                        H348S                     LHON
  mt*-ND5*    m.13511A\>T               392                        K392M                     Leigh-like syndrome
  mt*-ND5*    m.13730G\>A               465                        G465E                     LHON
  mt*-ND5*    m.14091A\>T               585                        K585N                     Developmental delay, seizure, hearing loss and diabetes
  mt*-ND6*    m.14600G\>A               25                         P25L                      LD with optic atrophy
  mt*-ND6*    m.14498T\>C               59                         Y59C                      LHON
  mt*-ND6*    m.14453G\>A               74                         A74V                      MELAS
  mt*-ND6*    m.14439G\>A               79                         P79S                      Mitochondrial Respiratory Chain Disorder
  mt*-ND6*    m.14430A\>G               82                         W82R                      TC

Note: DM: Diabetes Mellitus; AMegL: Acute Megakaryoblastic Leukemia; BSN: Bilateral Striatal Necrosis; CC: Colorectal cancer; CPEO: Chronic Progressive External Ophthalmoplegia; DEAF: Maternally inherited DEAFness or aminoglycoside-induced DEAFness; EXIT: Exercise Intolerance; HCM: Inherited Hypertrophic CardioMyopathy; LD: Leigh Disease; LHON: Leber Hereditary Optic Neuropathy; MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes; MIDD: Maternally Inherited Diabetes and Deafness; MILS: Maternally Inherited Leigh Syndrome; MLASA: Mitochondrial Myopathy, Lactic Acidosis, and Sideroblastic Anemia; MM: Mitochondrial Myopathy; PC: Prostate Cancer; PD: Parkinson's Disease; PEG: Pseudoexfoliation Glaucoma; PEO: Progressive External Ophthalmoplegia; sCJD: sporadic Creutzfeldt-Jakob disease; SNHL: Sensorineural Hearing Loss; TC: Thyroid Cancer.

10.1371/journal.pone.0177403.t004

###### Reported, disease-associated missense mutations in aligned codons positions with variable amino acid residues along primate evolution resulting in amino acid changes with similar physicochemical properties according to TreeSAAP.

![](pone.0177403.t004){#pone.0177403.t004g}

  Gene        Nucleotide substitution   Codon position in humans   Amino acid substitution   Associated phenotype in humans
  ----------- ------------------------- -------------------------- ------------------------- ------------------------------------------
  mt*-ATP6*   m.8836A\>G                104                        M104V                     LHON
  mt*-ATP6*   m.8890A\>G                122                        K122E                     Juevnile-onset metabolic syndrome
  mt*-CO1*    m.6267G\>A                122                        A122T                     PC
  mt*-CO1*    m.6285G\>A                128                        V128I                     PC
  mt*-CO1*    m.6721T\>C                273                        M273T                     Acquired Idiopathic Sideroblastic Anemia
  mt*-CO1*    m.6742T\>C                280                        I280T                     Acquired Idiopathic Sideroblastic Anemia
  mt*-CO1*    m.7080T\>C                393                        F393L                     PC
  mt*-CO2*    m.7587T\>C                1                          M1T                       MELAS
  mt*-CO3*    m.9438G\>A                78                         G78S                      LHON
  mt*-CO3*    m.9957T\>C                251                        F251L                     PEM / MELAS / NAION
  mt*-ND2*    m.4648T\>C                60                         F60S                      PEG
  mt*-ND2*    m.4852T\>A                128                        L128Q                     LHON
  mt*-ND3*    m.10086A\>G               10                         N10D                      Hypertensive end-stage renal disease
  mt*-ND5*    m.13271T\>C               312                        L312P                     EXIT

Note: EXIT: Exercise Intolerance; LHON: Leber Hereditary Optic Neuropathy; MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes; NAION: non‐arteritic ischaemic optic neuropathy; PC: Prostate Cancer; PEG: Pseudoexfoliation Glaucoma; PEM: Progressive encephalopathy.

Discussion {#sec012}
==========

Primate phylogeny {#sec013}
-----------------

Well-resolved phylogenies are necessary for tracing character evolution in morphological, physiological, ecological, biogeographic, behavioral and molecular studies \[[@pone.0177403.ref044]\]. This can be achieved by the continuous input of primate genomic data (nuclear and mitochondrial) from which more robust and reliable phylogenetic topologies can be reconstructed \[[@pone.0177403.ref045]--[@pone.0177403.ref047]\]. The ML topology herein provided ([S1 Fig](#pone.0177403.s001){ref-type="supplementary-material"}), was largely consistent with previous ones \[[@pone.0177403.ref040]--[@pone.0177403.ref042],[@pone.0177403.ref046]--[@pone.0177403.ref053]\] and was valuable for mapping nucleotide and amino acid changes and assessing the evolutionary conservation of codons and amino acids.

Evolutionary constraints on mt-genes {#sec014}
------------------------------------

Our findings, based on the frequency of the dN/dS ratio, showed that a large fraction of codon positions (88.9%) had been subjected to negative selection along primate radiation, in agreement with the postulation that mt-genes evolved under a strong purifying selection \[[@pone.0177403.ref054],[@pone.0177403.ref055]\]. Codons under negative selection were particularly concentrated in the highly-conserved genes of complex IV (mt-*CO1*, mt-*CO2* and mt-*CO3*) and mt-*ND4L*, while mt-*ATP8* and mt-*ND6* showed the lowest proportions of codons under negative selection. Reports on several mammalian orders, amphibians, birds and reptiles also found Complex IV and mt-*ND4L* to be highly conserved and mt-*ATP8* and mt-*ND6* as the most variable mt-genes \[[@pone.0177403.ref008],[@pone.0177403.ref056],[@pone.0177403.ref057]\]. This divergent pattern of molecular conservation and variation has been apparently constant at least from the beginning of tetrapod diversification. Furthermore, gene size and evolutionary conservation were found to be positively correlated as was the case of mt-*CO1*, in agreement with the proposition that the length of coding region of a gene affects its evolutionary rate \[[@pone.0177403.ref058]--[@pone.0177403.ref060]\] and is positively correlated with essentiality \[[@pone.0177403.ref061]\].

The four genes with the highest concentration of codons under negative selection did not show indels, while, on the other hand, *mt-ND6* showed 20 indels that took place as independent evolutionary events. The high conservation of complex IV genes and mt-*ND4L* indicated that mutations affecting these genes were likely to be more drastically adverse for fitness than mutations in other genes. In fact, complex IV genes and mt-*ND4L* did not show any mutation corresponding to a confirmed, disease-associated mutation in humans. Altogether, these findings suggested that these missense mutations have been consistently eliminated along the evolution of the non-human primates herein studied, while other missense mutations, corresponding to reported, disease-associated mutations in humans have been maintained.

Disease-associated mt-mutations in humans within an evolutionary context in the primates {#sec015}
----------------------------------------------------------------------------------------

Several mt-mutations have been associated with human diseases \[[@pone.0177403.ref062]\] mainly with common adult forms of inherited neurological disorders \[[@pone.0177403.ref063]\]. Most confirmed mt-mutations affect tRNA genes and the translational efficiency of mitochondria impairing the proper functioning of four OXPHOS enzyme complexes \[[@pone.0177403.ref018]\]. Conversely, the effects of mt-mutations on protein-coding genes are more restricted and more difficult to be clearly identified \[[@pone.0177403.ref018]\] and mutations in only 28 codon positions are generally considered pathogenic by the mitochondrial research community (MITOMAP database \[[@pone.0177403.ref017]\]).

In this study, confirmed, disease-associated mt-mutations showed higher scores of predicted pathogenicity than reported ones and all of them were located in aligned codon positions under strong negative selection, and almost all in highly conserved positions along primate evolution ([Table 3](#pone.0177403.t003){ref-type="table"}). This finding suggested that similar mutations in other primate species would be likely to be pathogenic and impair fitness. In fact, most of these 28 codons were responsible for critical regions of protein domains directly involved in OXPHOS. This was the case of the mt-*ATP6* region encoding a transmembrane domain of the ATP synthase F~0~ subunit involved in proton translocation \[[@pone.0177403.ref064]\]. One mutation (m.8993T\>C) affecting this region has been etiologically associated with NARP, Leigh Disease, MILS and other diseases in humans \[[@pone.0177403.ref065]\]. Similarly, m.15579A\>G, affecting one mt-*CYB* region encoding a protein segment exposed to the intermembrane space bearing an ubiquinone binding site has been etiologically associated with multisystem disorder and EXIT in humans \[[@pone.0177403.ref003],[@pone.0177403.ref066],[@pone.0177403.ref067]\].

Only two confirmed disease-associated mutations, both in mt-*ND3* (m.10158T\>C, S34P; m.10191T\>C, S45P), were located in highly variable codon positions, flanking a highly conserved mt-*ND3* loop domain ([S3 Table](#pone.0177403.s007){ref-type="supplementary-material"} and [S2 Fig](#pone.0177403.s002){ref-type="supplementary-material"}). Previous predictions about their pathogenicity have been contradictory \[[@pone.0177403.ref013],[@pone.0177403.ref068]\] while a previous report has indicated that m.10158T\>C affected an extremely conserved amino acid position among mammals \[[@pone.0177403.ref069]\], a finding that was not corroborated in the primates herein studied. A previous report proposed that a hydrophobic residue like proline at position 45 would disrupt folding of the NADH-ubiquinone oxidoreductase chain 3 and showed that only hydrophilic amino acids were present across different taxa in this position \[[@pone.0177403.ref070]\]. Missense mt-mutations, however, resulting in residues with manifold physicochemical properties, including hydrophobic amino acids other than proline have been identified in this study. It is therefore likely that mutations at this site have not been severely detrimental for most primates or, alternatively, a proline-45 residue may be specifically disruptive for folding of NADH-ubiquinone oxidoreductase chain 3.

Only two confirmed disease-associated missense mutations in humans, both in mt-*ND1* (m.3635G\>A; S110N and m.3700G\>A; A132T), showed similar counterparts in other primates, in apparently healthy sooty mangabeys (*Cercocebus atys*) and Bornean orangutans (*Pongo pygmaeus*), respectively \[[@pone.0177403.ref071],[@pone.0177403.ref072]\]. This latter mutation was located in a highly conserved mt-*ND1* region, comprising approximately 27 codons, encoding a loop domain exposed to the intermembrane space, a critical region for NADH catalytic function \[[@pone.0177403.ref073],[@pone.0177403.ref074]\]. The presence of a polar amino acid like threonine at position 132 in Bornean orangutans was unexpected, since this position appeared to be invariably occupied by alanine, a non-polar amino acid, in several mammals other than primates (mouse, rabbit, horse, cattle, whale, seal, cat and platypus), other animals (nematodes, sea-urchins, fish and chickens), and plants; the only exception being found in two fungi species with the polar amino acid serine \[[@pone.0177403.ref071]\]. Conversely, m.3635G\>A (S110N) occurred in an adjacent region to the loop domain, encoding a slightly more variable transmembrane domain, presumably without a critical relevance for NADH function \[[@pone.0177403.ref074]\].

Occurrence of some pathogenic alleles for humans in healthy gorillas, chimpanzees and macaques has been documented for several nuclear genes \[[@pone.0177403.ref075],[@pone.0177403.ref076]\]. It is not completely understood how these alleles might be innocuous for non-human primates; it is speculated that compensatory changes in other genome regions or environmental differences might neutralize their effects \[[@pone.0177403.ref022],[@pone.0177403.ref076]\]. A third explanation, postulating the existence of different physiological demands between species, might explain why an allele responsible for low ATP production might be severely detrimental to a species with a high metabolic demand, like *Homo sapiens*, but not to species with low metabolisms like the slow lories (genus *Nycticebus*; \[[@pone.0177403.ref022]\]). Orangutans show an extremely low rate of energy use, even lower relative to body mass, than nearly any eutherian mammal ever studied \[[@pone.0177403.ref077]\]. This may explain why the S110N substitution in the NADH-ubiquinone oxidoreductase chain 1, affecting a highly conserved polypeptide domain, might be tolerated in orangutans but not in other mammals.

Interestingly, the mt-*ATP6* start codon changed from ATG (coding for methionine) to GTG (coding for valine) in two non-anthropoid (strepsirrhine) species, the Wallace's tarsier (*Tarsius wallacei*) and the Hubbard\'s sportive lemur (*Lepilemur hubbardorum*). In humans, the first, GTG, codon of mt-*ATP6* does not completely impair gene transcription and translation, but is reportedly associated with LHON \[[@pone.0177403.ref078]\]. Unfortunately, it was not possible to access whether the GTG condition might be a common finding in these two species due to dearth of mt-*ATP6* data.

Differently from confirmed disease-associated mutations, the reported ones were not especially concentrated in highly conserved codon positions, suggesting that an important fraction of them have not effectively reduced organismal fitness along primate diversification. Additionally, they showed lower predicted pathogenicity scores than confirmed disease-associated mutations and 45% of them also showed similar substitutions in other primates, including very closely related species, like great apes and other species of the genus *Homo*. This was the case of the m.3496G\>T (A64S), affecting mt-*ND1* of Japanese families and associated with LHON \[[@pone.0177403.ref079]\]. Codon 64 was highly variable along primate evolution, but more recently coded for serine in the ancestral hominid and all descendant hominid species except *Homo sapiens* and *H*. *neanderthalensis* in which an S64A mutation occurred. The m.3496G\>T (A64S) found in Japanese families can thus be interpreted as an evolutionary reversion ([Fig 5B](#pone.0177403.g005){ref-type="fig"}).

In fact, all reported disease-associated mutations in humans with similar substitutions in the reference sequence of *Homo* species other than *Homo sapiens* (m.6150G\>A, m.8021A\>G, m.15077G\>A, m.3421G\>A, m.3496G\>T, m.4659G\>A, m.10398A\>G, m.11253T\>C and m.13528A\>G) occurred in highly variable aligned codon positions. These findings indicated that they must have been someway compatible with adequate fitness in our congeneric extinct relatives.

It must be noted that the human reference sequence corresponds to a single individual of European descent with some rare polymorphisms \[[@pone.0177403.ref080]\]. It is likely that the reference sequences of non-human primate species might contain nucleotide variants that do not code for the most common amino acids in these species but population data on their mitochondrial genome are not presently available. However, a phylogenetic approach might indicate the persistence of variants along phyletic diversification, suggesting that they were probably frequent in ancestral populations \[[@pone.0177403.ref081]\]. This was the case of most reported, disease-associated amino acid variants with counterparts in non-human primates (n = 68; 75.6%) which were found to be transmitted to more than one species.

Several methods have been used for predicting the pathogenicity and severity of mutations in humans \[[@pone.0177403.ref082]--[@pone.0177403.ref086]\]; some of them applied to the mitochondrial genome \[[@pone.0177403.ref013]\]. These frequently considered evolutionary data predicted functional properties and protein structure \[[@pone.0177403.ref020],[@pone.0177403.ref021]\], although some of these reports did not include topological analyses of phylogenies like determining ancestry, number and independence of evolutionary events and their polarity. Our findings showed that several reported disease-associated mutations in humans appeared to be recurrent along primate diversification in closely related species that diverged from humans less than 80 million years ago. It is therefore likely that the reported disease-associated mutations in humans in extremely conserved aligned codon positions along primate evolution are more likely to be actually pathogenic. Fourteen associated mutations with MELAS, 13 with LHON, 9 with LD, 5 with EXIT, and 30 with other pathologies fitted this criterion that might be helpful for distinguishing effectively pathogenic mutations from polymorphisms. Similarly, 14 other reported disease-associated mutations in humans occurred in variable residue positions along primate evolution resulting in amino acid changes with similar physicochemical properties. Thirteen of these positions were found to be under negative selection with SLAC ([S3 Table](#pone.0177403.s007){ref-type="supplementary-material"}), suggesting that they might be critically relevant for mitochondrial function.
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